{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelogenous+Leukemia%2C+Acute&page=6", "query": { "condition": "Myelogenous Leukemia, Acute", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 2503, "total_pages": 251, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelogenous+Leukemia%2C+Acute&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelogenous+Leukemia%2C+Acute&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T01:36:56.072Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00357032", "title": "PXD101 in Treating Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Recurrent Adult Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "belinostat", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2006-05", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2018-04-17", "last_synced_at": "2026-10-09T01:36:56.072Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00357032" }, { "nct_id": "NCT00053963", "title": "FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Choroid Plexus Tumor", "Childhood Chronic Myelogenous Leukemia", "Childhood Craniopharyngioma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Spinal Cord Neoplasm", "Childhood Supratentorial Ependymoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Refractory Chronic Lymphocytic Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 30, "start_date": "2002-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-09T01:36:56.072Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00053963" }, { "nct_id": "NCT07007312", "title": "Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine (AZA)", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Cytarabine (Ara-C)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kura Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1300, "start_date": "2025-09-26", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-09T01:36:56.072Z", "location_count": 43, "location_summary": "Gilbert, Arizona • Clovis, California • La Jolla, California + 36 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Clovis", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07007312" }, { "nct_id": "NCT02396134", "title": "Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Hodgkin Lymphoma", "Adult Non-Hodgkin Lymphoma", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Cytomegaloviral Infection", "Hematopoietic and Lymphoid Cell Neoplasm", "HLA-A*0201 Positive Cells Present", "Myelodysplastic Syndrome", "Adult Lymphoblastic Lymphoma", "Chronic Lymphocytic Leukemia", "Myelofibrosis", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "CMVpp65-A*0201 peptide vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 61, "start_date": "2015-05-21", "completion_date": "2024-09-19", "has_results": true, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-10-09T01:36:56.072Z", "location_count": 5, "location_summary": "Duarte, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02396134" }, { "nct_id": "NCT00085709", "title": "S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "gemtuzumab ozogamicin", "type": "DRUG" }, { "name": "observation", "type": "OTHER" }, { "name": "Cytosine arabinoside", "type": "DRUG" }, { "name": "Daunomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 637, "start_date": "2004-07", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2015-09-30", "last_synced_at": "2026-10-09T01:36:56.072Z", "location_count": 255, "location_summary": "Anchorage, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 161 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085709" }, { "nct_id": "NCT04023071", "title": "FT516 in Subjects With Advanced Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "B-cell Lymphoma" ], "interventions": [ { "name": "FT516", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2019-10-04", "completion_date": "2023-10-23", "has_results": false, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-10-09T01:36:56.072Z", "location_count": 7, "location_summary": "Phoenix, Arizona • San Diego, California • Denver, Colorado + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04023071" }, { "nct_id": "NCT03814005", "title": "A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndromes", "Leukemia, Myelomonocytic, Chronic", "Leukemia, Myeloid, Acute", "Renal Insufficiency", "Liver Disease", "Neoplasms" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2019-07-10", "completion_date": "2022-04-19", "has_results": true, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-10-09T01:36:56.072Z", "location_count": 2, "location_summary": "New York, New York • Chapel Hill, North Carolina", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03814005" }, { "nct_id": "NCT03110354", "title": "DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute", "Leukemia, Lymphocytic, Acute" ], "interventions": [ { "name": "DS-3201b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2017-04-05", "completion_date": "2021-03-09", "has_results": true, "last_update_posted_date": "2024-01-31", "last_synced_at": "2026-10-09T01:36:56.072Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03110354" }, { "nct_id": "NCT00003005", "title": "Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Cordycepin", "type": "DRUG" }, { "name": "Deoxycoformycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "1997-12", "completion_date": "2001-03", "has_results": false, "last_update_posted_date": "2012-06-13", "last_synced_at": "2026-10-09T01:36:56.072Z", "location_count": 13, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003005" }, { "nct_id": "NCT04872595", "title": "A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Lymphoid Leukemia (ALL)", "Myelodysplastic Syndromes (MDS)" ], "interventions": [ { "name": "Personalized rATG (P-rATG)", "type": "OTHER" }, { "name": "Hyper fractionated total body irradiation", "type": "RADIATION" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GCSF", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "OTHER", "RADIATION", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 59, "start_date": "2021-04-30", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-09T01:36:56.072Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04872595" } ] }